Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injections like Mounjaro and Wegovy commonly cause gastrointestinal side effects, including nausea, vomiting, diarrhoea and constipation. These are the most frequently reported reactions in clinical trials and tend to be most noticeable when starting treatment or after a dose increase, often settling within a week or two as your body adjusts. These medicines are prescription-only, which means a clinician assesses your full health picture before any treatment begins — and that conversation is precisely where side effects, risks and your individual history get properly weighed up. The NHS patient information on tirzepatide and the equivalent page for semaglutide cover the known side-effect profile in plain language.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The GLP-1 medicines licensed in the UK for weight management (tirzepatide (Mounjaro) and semaglutide (Wegovy)) both work partly by slowing the rate at which the stomach empties. That mechanism is effective for reducing appetite, and it is also the reason the gut tends to register the adjustment first. Nausea is the most commonly reported side effect in clinical trials, followed by loose stools or diarrhoea, constipation, burping and acid reflux. Headache, fatigue and dizziness appear less often but are recognised reactions, particularly in the early weeks. If you want a thorough overview before starting, our page on whether there are side effects to weight loss injections walks through what the evidence says in plain terms.
Injection-site reactions (mild redness, itching or a small bump where you inject) are possible too. Rotating your injection site between the abdomen, thigh and upper arm helps reduce these; our guide to taking weight loss injections covers injection technique in more detail.
The important context: these effects are generally mild to moderate in intensity. In the SURMOUNT-1 trial involving thousands of adults, the large majority of participants who experienced GI side effects reported them as manageable, and discontinuation due to side effects was relatively low. Symptoms typically cluster around the start of treatment and each dose step, then ease. The titration approach (beginning at 2.5mg for tirzepatide, for instance, and moving up in stages) exists specifically to give your system time to settle.
Serious side effects are infrequent but real, and being aware of them is part of using these medicines safely. In January 2026, the MHRA issued a Drug Safety Update on GLP-1 receptor agonists specifically flagging acute pancreatitis as a known risk: the regulator advised patients and clinicians to be alert to severe, persistent abdominal pain that may radiate to the back, with or without vomiting. If you experience that, stop the injection and seek urgent medical attention rather than waiting to see if it passes.
Other symptoms worth taking seriously include signs of an allergic reaction (swelling of the face or throat, difficulty breathing), significant dehydration caused by prolonged vomiting or diarrhoea, and symptoms pointing to gallbladder problems such as upper-right abdominal pain, fever or jaundice. People with type 2 diabetes who are also on certain diabetes medicines should discuss hypoglycaemia risk with their prescriber before starting.
A practical checking habit that takes under a minute: once a week, scan the injection site before you inject, any persistent lump, redness or hardness worth mentioning should be flagged to your prescriber at the next contact. Small observations like this are easy to overlook and easy to report. Our detailed side-effect resource goes into each of these areas with fuller clinical context if you want to read further.
Most nausea or loose stools after a dose change do not need a GP visit. The situations that do require prompt attention are different in character: they are more intense, more persistent, or accompanied by other warning signs. Seek medical help (same day or via 999 if severe) if you develop any of the following while taking a weight loss injection:
Severe stomach pain that does not settle and spreads to your back (pancreatitis concern); inability to keep any fluids down for more than 24 hours (dehydration risk); signs of a severe allergic reaction; chest pain or unexplained shortness of breath; yellowing of the skin or eyes; or any thoughts of self-harm or mood changes that feel out of character.
You can also report suspected side effects formally to the MHRA through the Yellow Card scheme at yellowcard.mhra.gov.uk. The scheme is open to patients and carers, not just healthcare professionals, and reports genuinely contribute to how these medicines are monitored post-approval. If you have concerns between prescriber reviews, our aftercare team is available seven days a week.
Both medicines share the same broad GI side-effect profile because both slow gastric emptying. The headline difference is mechanism: tirzepatide activates two receptors (GIP and GLP-1) while semaglutide activates one. Whether that translates into a meaningfully different day-to-day tolerability experience varies between individuals, and the clinical trials used different designs, so a clean like-for-like comparison is difficult. What the evidence does show is that both carry the same categories of risk, and the same principles (slow titration, staying hydrated, not forcing yourself to eat if nauseated) apply to both. For a closer look at how these reactions present across both medicines, our guide to what the side effects of weight loss injections actually are covers the detail medicine by medicine.
There is one difference worth knowing about regarding contraception. NHS guidance notes that for tirzepatide specifically, women taking the oral contraceptive pill should use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because slowed gastric emptying may reduce pill absorption. No equivalent advisory applies to semaglutide. If this applies to you, raise it at consultation; our overview of weight loss injections touches on this alongside other practical considerations.
Deciding which medicine is appropriate (and whether either is right for you at all) is a clinical decision. The NHS England guidance on weight management injections outlines the clinical framework that prescribers work within. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. If you'd like to explore whether treatment might suit you, checking your eligibility starts with a free consultation, and questions about what the long term effects of weight loss injections look like are very much part of the conversation we encourage you to bring.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.